Follow
Xavier Duportet
Xavier Duportet
Unknown affiliation
Verified email at eligo-bioscience.com
Title
Cited by
Cited by
Year
Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials
D Bikard, CW Euler, W Jiang, PM Nussenzweig, GW Goldberg, X Duportet, ...
Nature biotechnology 32 (11), 1146-1150, 2014
7152014
A platform for rapid prototyping of synthetic gene networks in mammalian cells
X Duportet, L Wroblewska, P Guye, Y Li, J Eyquem, J Rieders, T Rimchala, ...
Nucleic acids research 42 (21), 13440-13451, 2014
1142014
The biological interpretation of metabolomic data can be misled by the extraction method used
X Duportet, RBM Aggio, S Carneiro, SG Villas-Bôas
Metabolomics 8 (3), 410-421, 2012
1052012
Rapid, modular and reliable construction of complex mammalian gene circuits
P Guye, Y Li, L Wroblewska, X Duportet, R Weiss
Nucleic acids research 41 (16), e156-e156, 2013
962013
Improving sequence-specific antimicrobials by blocking dna repair
D Bikard, CUI Lun, X Duportet, JF Rodriguez
642017
Development of sequence-specific antimicrobials based on programmable CRISPR-Cas nucleases
D Bikard, C Euler, W Jiang, PM Nussenzweig, GW Goldberg, X Duportet, ...
Nature biotechnology 32 (11), 1146, 2014
442014
Design and connection of robust genetic circuits
A Randall, P Guye, S Gupta, X Duportet, R Weiss
Methods in enzymology 497, 159-186, 2011
332011
Comparison of integrases identifies Bxb1-GA mutant as the most efficient site-specific integrase system in mammalian cells
B Jusiak, K Jagtap, L Gaidukov, X Duportet, K Bandara, J Chu, L Zhang, ...
ACS Synthetic Biology 8 (1), 16-24, 2019
192019
Voices of biotech leaders
K Bosley, C Casebourn, P Chan, J Chen, M Chen, G Church, J Cumbers, ...
Nature biotechnology 39 (6), 654-660, 2021
42021
Optimized vector for delivery in microbial populations
A Decrulle, JF Rodriguez, X Duportet, D Bikard
US Patent 10,808,254, 2020
32020
Developing new tools and platforms for mammalian synthetic biology: From the assembly and chromosomal integration of complex DNA circuits to the engineering of artificial …
X Duportet
Université Paris Diderot (Paris 7), 2014
22014
Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders
X Duportet, A Decrulle, C del Carmen Gil-Cruz, CI Pérez-Shibayama, ...
US Patent App. 17/716,313, 2022
2022
Sequence-specific antimicrobials by blocking DNA repair
D Bikard, L Cui, X Duportet, JF Rodriguez
US Patent 11,357,831, 2022
2022
Microbiome modulation of a host by delivery of dna payloads with minimized spread
JF Rodriguez, X Duportet
US Patent App. 17/565,060, 2022
2022
Chimeric receptor binding proteins resistant to proteolytic degradation
JF Rodriguez, X Duportet
US Patent App. 17/564,625, 2022
2022
Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders
X Duportet, A Decrulle, C del Carmen Gil-Cruz, CI Pérez-Shibayama, ...
US Patent App. 17/501,110, 2022
2022
Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders
X Duportet, A Decrulle, C del Carmen Gil-Cruz, CI Pérez-Shibayama, ...
US Patent 11,224,621, 2022
2022
Optimized vector for delivery in microbial populations
A Decrulle, JF Rodriguez, X Duportet, D Bikard
US Patent App. 17/356,079, 2021
2021
Bacterial delivery vehicle, process of production and uses thereof
A Decrulle, X Duportet, I Stzepourginski
US Patent App. 17/406,437, 2021
2021
Elimination of colonic bacterial driving lethal inflammatory cardiomyopathy
X Duportet, C del Carmen Gil-Cruz, CI Pérez-Shibayama, B Ludewig
US Patent App. 17/225,854, 2021
2021
The system can't perform the operation now. Try again later.
Articles 1–20